Home>>Signaling Pathways>> GPCR/G protein>> mAChR>>Sofpironium bromide

Sofpironium bromide (Synonyms: BBI 4000)

Catalog No.GC63196

Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH).

Products are for research use only. Not for human use. We do not sell to patients.

Sofpironium bromide Chemical Structure

Cas No.: 1628106-94-4

Size Price Stock Qty
1mg
$63.00
In stock
5mg
$140.00
In stock
10mg
$224.00
In stock
25mg
$403.00
In stock
50mg
$605.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes[1].

Sofpironium bromide is metabolized mainly through non-enzymatic hydrolysis, and also through oxidative metabolism via CYP2D6 and CYP3A4[1].

Sofpironium bromide exhibits anticholinergic activity by inhibiting the contractile activity of guinea pig ileal tissue in a concentration-dependent manner. In a rat model, Sofpironium bromide reduces footpad sweating induced by Pilocarpine (a muscarinic receptor agonist)[1].

[1]. Julia Paik, et al. Sofpironium Bromide: First Approval. Drugs. 2020 Dec;80(18):1981-1986.

Reviews

Review for Sofpironium bromide

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sofpironium bromide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.